Diakonos Oncology Announces First Patients Dosed in Phase 1/2 DOC-RM Study of DOC1021 in Refractory Melanoma
July 30, 2026
Press Releases
Diakonos Oncology Shares Updated DOC1021 GBM Survival Data and Unveils Melanoma Clinical Study at ASCO 2026
June 5, 2026
Diakonos Oncology Awarded Fast Track Designation by FDA for DOC1021 (dubodencel) in Unresectable or Metastatic Cutaneous Melanoma
May 6, 2026
Diakonos Oncology to Present Corporate Overview and Participate in Panel at 2026 Biotech Showcase
December 15, 2025
Diakonos Oncology Awarded Multi-Million-Dollar Research Grant by the Cancer Prevention and Research Institute of Texas to Advance DOC1021 in Refractory Melanoma
December 10, 2025
Diakonos Oncology Presents Promising Preliminary Data from Phase 1 Study of DOC1021 Cell-Based Immunotherapy in Pancreatic Cancer at Society for Immunotherapy of Cancer 40th Annual Meeting
November 7, 2025
Pancreatic Cancer Clinical Trial Data for Diakonos Oncology’s DOC1021 Cell-Based Immunotherapy to be Presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
October 27, 2025
Donna Rill New Hire
August 12, 2025
Phase 2 GBM Trial First Patient
July 22, 2025
Diakonos Oncology Presents Promising Phase I Results of Dubodencel (DOC1021) at the ASCO 2025 Annual Meeting
June 2, 2025
Diakonos Oncology Closes $20M financing to accelerate Phase 2 Glioblastoma Clinical Development Program
May 30, 2025
Diakonos Oncology Presents Phase I Analysis of DOC1021 at the 2025 American Academy of Neurology Annual Meeting
April 9, 2025
Diakonos Oncology to Present at Biotech Showcase 2025
January 10, 2025
Diakonos Oncology Appoints Laura Aguilar, M.D., Ph.D. as Chief Medical Officer
November 18, 2024
Neurosurgeon Joseph Georges, P.I. for Diakonos Oncology’s Phase 1 Trial of Its Unique Dendritic Cell Vaccine for Gliobastoma, Receives the CNS 2024 Rosenblum-Mahaley Clinical Research Award
October 15, 2024
CNS 2024 Conference Presentation: Diakonos Oncology’s Autologous Dendritic Cell Vaccine (DOC1021) Yields 93% 12-Month Survival for Glioblastoma Patients
October 1, 2024
Diakonos Oncology Announces Final Closing of Oversubscribed $11.4M Seed Financing to Advance Its Highly Differentiated Dendritic Cell Vaccine (DOC1021) into a Phase 2 Clinical Trial
August 26, 2024
Diakonos Oncology Receives FDA Fast Track Designation for Pancreatic Cancer Dendritic Cell Vaccine; Names Daniel D. Von Hoff, M.D. to Scientific Advisory Board
July 15, 2024
Diakonos Oncology CFO Anthony Baldor to Provide Corporate Update at BIO International Convention In San Diego, June 3 – 6, 2024
June 3, 2024
Diakonos Oncology’s Unique Dendritic Cell Vaccine (DOC1021) Improves Survival Compared to Standard of Care in Phase 1 Trial for Glioblastoma
April 9, 2024
Diakonos Oncology Appoints Biotech Veteran Anthony Baldor as Chief Financial Officer
February 26, 2024
Diakonos Oncology Names Paul Lammers, M.D., Veteran BioPharma Senior Executive, to its Board of Directors
February 20, 2024
Diakonos Receives FDA Orphan Drug Designation
January 2, 2024
Diakonos Completes Phase 1 GBM Recruitment
November 29, 2023
Ian H. Bellayr, Ph.D., Joins as Chief Regulatory Officer
November 17, 2023
Awarded TLSF Top 10 Most Promising Life Science Companies
November 8, 2023
Diakonos Awarded FDA Fast Track Designation
October 17, 2023
Connect with us on social
